1. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021

   • Laura Evans
   • Andrew Rhodes
   • Mitchell Levy

   Guidelines 02 October 2021 Pages: 1181 - 1247

   

2. Sodium chloride or Plasmalyte-148 evaluation in severe diabetic ketoacidosis (SCOPE-DKA): a cluster, crossover, randomized, controlled trial

   • Mahesh Ramanan
   • Antony Attokaran
   • the SCOPE-DKA Collaborators and Queensland Critical Care Research Network (QCCRN)

   Original 05 October 2021 Pages: 1248 - 1257

   

3. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial

   • Ivan O. Rosas
   • George Diaz
   • Julie K. Olsson

   Original Open access 05 October 2021 Pages: 1258 - 1270

   

4. Individualised versus conventional glucose control in critically-ill patients: the CONTROLING study—a randomized clinical trial

   • Julien Bohé
   • Hassane Abidi
   • on behalf of the CONTROLe INdividualisé de la Glycémie (CONTROLING) Study Group

   Original Open access 29 September 2021 Pages: 1271 - 1283

   

5. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial

   • Pierre-François Laterre
   • Peter Pickkers
   • the AdrenOSS-2 study participants

   Original 04 October 2021 Pages: 1284 - 1294

   

6. Effect of oral chlorhexidine de-adoption and implementation of an oral care bundle on mortality for mechanically ventilated patients in the intensive care unit (CHORAL): a multi-center stepped wedge cluster-randomized controlled trial

   • Craig M. Dale
   • Louise Rose
   • Brian H. Cuthbertson

   Original 05 October 2021 Pages: 1295 - 1302

   

7. High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial

   • Elena Garbero
   • Sergio Livigni
   • GiViTI

   Original 03 October 2021 Pages: 1303 - 1311

   

8. Fluid management in diabetic ketoacidosis: new tricks for old dogs?

   • Bruno Adler Maccagnan Pinheiro Besen
   • Willem Boer
   • Patrick M. Honore

   Editorial 05 October 2021 Pages: 1312 - 1314

   

9. The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?

   • Kate C. Tatham
   • Manu Shankar-Hari
   • Yaseen M. Arabi

   Editorial 07 October 2021 Pages: 1315 - 1318

10. The goal of personalized glucose control in the critically ill remains elusive

    • James S. Krinsley
    • Adam M. Deane
    • Jan Gunst

    Editorial 17 September 2021 Pages: 1319 - 1321

11. Post-mortem dissection of COVID-19: a pathogenic role for macrophages?

    • Prasad P. Velu
    • Christopher D. Lucas
    • Andrew Conway Morris

    Understanding the Disease 01 September 2021 Pages: 1322 - 1325

    

12. Diagnosis of spontaneous intestinal perforation using point of care ultrasound

    • Ignacio Oulego-Erroz
    • Carlos Ocaña-Alcober
    • Sandra Terroba-Seara

    Imaging in Intensive Care Medicine 09 July 2021 Pages: 1326 - 1326

13. Behavioural artificial intelligence technology for COVID-19 intensivist triage decisions: making the implicit explicit

    • Jesse de Metz
    • Patrick J. Thoral
    • Bas van den Bogaard

    Letter Open access 25 August 2021 Pages: 1327 - 1328

    

14. Using the lung ultrasound score to monitor disease progression for COVID-19-associated ARDS

    • Maxime Nguyen
    • Guillaume Gaujard
    • the L. U. S. Study Group

    Letter 30 September 2021 Pages: 1329 - 1331

15. No clinically relevant removal of meropenem by cytokine adsorber CytoSorb^® in critically ill patients with sepsis or septic shock

    • Uwe Liebchen
    • Christina Scharf
    • the CytoMero collaboration team

    Letter Open access 14 September 2021 Pages: 1332 - 1333

    

16. Cytokine adsorption in severe, refractory septic shock

    • Pedro David Wendel Garcia
    • Matthias Peter Hilty
    • Marco Maggiorini

    Letter 01 September 2021 Pages: 1334 - 1336

    

17. COVID-19-associated invasive pulmonary aspergillosis: high incidence or difficult diagnosis?

    • Anahita Rouzé
    • Elise Lemaitre
    • Saad Nseir

    Correspondence 03 August 2021 Pages: 1337 - 1338

18. COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges

    • Juergen Prattes
    • Philipp Koehler
    • on behalf of the ECMM-CAPA Study Group

    Correspondence 01 September 2021 Pages: 1339 - 1340

19. Influenza and prophylactic antifungal therapy for aspergillosis: addressing some questions first

    • Anne Coste
    • Kahaia De Longeaux
    • Cécile Aubron

    Correspondence 10 August 2021 Pages: 1341 - 1342

20. Critical influenza and prophylactic antifungal therapy for aspergillosis: a nuanced approach to a pertinent infectious disease

    • Lore Vanderbeke
    • Katrien Lagrou
    • Joost Wauters

    Correspondence 04 October 2021 Pages: 1343 - 1344

21. Would my “Eriksen” wake up again?

    • Gentle Sunder Shrestha

    From the Inside 04 August 2021 Pages: 1345 - 1345